Remynd NV announced positive Phase IIa results for REM-127, targeting calcium homeostasis restoration in Alzheimer's disease, demonstrating reduced pathological tau, increased dopamine, and cognitive improvements. This first-in-class septin modulator trial supports its novel mechanism of action. Concurrently, Avidity Biosciences reported encouraging Phase I/II data showing reversal of disease progression in Duchenne muscular dystrophy patients treated with del-zota, an antibody-oligonucleotide conjugate, accompanied by functional improvements. Avidity also raised $150 million in a private placement to advance development programs.